A primer on effectiveness and efficacy trials

Clinical and Translational Gastroenterology

Volumn 5, Issue , 2014, Pages

  Singal, Amit G ^a,b   Higgins, Peter D R ^c   Waljee, Akbar K ^c,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ARTICLE; CLINICAL PRACTICE; COLORECTAL CANCER; DATA ANALYSIS; DRUG DESIGN; DRUG EFFICACY; HUMAN; INTERNAL VALIDITY; LIVER CELL CARCINOMA; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; STUDY DESIGN; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; INFORMATION PROCESSING; INTERVENTION STUDY; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICAL ANALYSIS;

EID: 84891763608     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2013.13     Document Type: Article

References (32)

1. Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics 1999; 15: 423-434. (Pubitemid 29210946)
2. Fritz JM, Cleland J. Effectiveness versus efficacy: more than a debate over language. J Orthop Sports Phys Ther 2003; 33: 163-165. (Pubitemid 36871437)
3. El-Serag HB, Talwalkar J, Kim WR. Efficacy, effectiveness, and comparative effectiveness in liver disease. Hepatology 2010; 52: 403-407.
4. Klabunde CN, Brown M, Ballard-Barbash R et al. Cancer Screening-United States, 2010; 27 January 2012 2012.
5. Singal AG, Yopp A, S Skinner C et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med 2012; 27: 861-867.
6. Singal AG, Yopp AC, Gupta S et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) 2012; 5: 1124-1130.
7. Steinwachs D, Allen JD, Barlow WE et al. National Institutes of Health state-of-the-science conference statement: enhancing use and quality of colorectal cancer screening. Ann Intern Med 2010; 152: 663-667.
8. Singal AG, Nehra M, Adams-Huet B et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol 2013; 108: 425-432.
9. Singal A, Volk ML, Waljee A et al. Meta-analysis: surveillance with ultrasound for earlystage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47.
10. Singal AG, Conjeevaram HS, Volk ML et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012; 21: 793-799.
11. Singal AG, Volk ML, Jensen D, Di Bisceglie A, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clinical Gastroenterology and Hepatology 2010; 8: 280-288.
12. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the united states. Hepatology 50: 1750-1755.
13. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
14. Tan D, Yopp AC, Beg MS, Gopal P, Singal AG. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the united states. Alimentary Pharmacology & Therapeutics 2013; 38: 703-712.
15. Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials 2009; 10: 37.
16. Abraham J. Use of 'efficacy' and 'effectiveness' often misleading and may skew reimbursement decisions. Context Matters advance online publication, 6 November 2012; http://globenewswire.com/news-release/2012/11/06/502781/10011322/ en/Use-of-Efficacyand-Effectiveness-Often-Misleading-and-May-Skew-Reimbursement- Decisions.html.
17. Streiner D, Norman G. Efficacy and effectiveness trials. Community Oncology 2009; 6: 472-474.
18. Thorpe KE, Zwarenstein M, Oxman AD et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009; 62: 464-475.
19. Elmunzer BJ, Scheiman JM, Lehman GA et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012; 366: 1414-1422.
20. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001; 48: 272-282. (Pubitemid 32141856)
21. Su C, Lewis JD, Goldberg B et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007; 132: 516-526.
22. Elmunzer BJ, Hayward RA, Schoenfeld PS et al. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and metaanalysis of randomized controlled trials. PLoS Med 2012; 9: e1001352.
23. Rangwalla SC, Waljee AK, Higgins PD. Voting With their Feet (VWF) endpoint: a metaanalysis of an alternative endpoint in clinical trials, using 5-ASA induction studies in ulcerative colitis. Inflamm Bowel Dis 2009; 15: 422-428.
24. Sussman JB, Hayward RA. An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. BMJ 2010; 340: c2073.
25. Ibrahim JG, Chu H, Chen MH. Missing data in clinical studies: issues and methods. J Clin Oncol 2012; 30: 3297-3303.
26. Kaambwa B, Bryan S, Billingham L. Do the methods used to analyse missing data really matter? An examination of data from an observational study of Intermediate Care patients. BMC Res Notes 2012; 5: 330.
27. Waljee AK, Mukherjee A, Singal AG et al. Comparison of modern imputation methods for missing laboratory data in medicine. BMJ Open 2013; 3: e002847.
28. Flay BR, Biglan A, Boruch RF et al. Standards of evidence: criteria for efficacy, effectiveness and dissemination. Prev Sci 2005; 6: 151-175. (Pubitemid 43487950)
29. Zwarenstein M, Treweek S, Gagnier JJ et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008; 337: a2390.
30. Rothwell PM. External validity of randomised controlled trials: 'to whom do the results of this trial apply?' Lancet 2005; 365: 82-93. (Pubitemid 40082150)
31. Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med 2009; 151: 203-205.
32. Gartlehner G, Hansen RA, Nissman D et al. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol 2006; 59: 1040-1048. (Pubitemid 44374310)